Valuation
- Market cap
- 1,000
- Revenue TTM
- $1,270,000
- Net income TTM
- $-58,800,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -4,629.92%
- Debt to equity
- -0.51
Trading
- Volume
- 200,000
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 12,170,000
- Stochastic %K
- —
- Beta
- 0.62
- Analysts
- —
- Price target
- —
Company profile
Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is...
Show more
Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 484 395 2440
- Website
- https://www.baudaxbio.com
- Address
- 490 Lapp Road, Malvern, United States
Latest news
No headlines yet.
